Abstract Details
|
Kevin Talbot, MD, PhD
(Univrsity of Oxford)
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Lucy E. Farrimond, PhD, BMBCh (NDCN, University of Oxford) | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| Massimo Filippi, MD, FÂ鶹´«Ã½Ó³» (Ospedale San Raffaele, Neuroimaging Research Unit) | Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. |